Clinical Trials

BreastGastrointestinalThoracic

236 enrolled 21 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

NCT00003867 2018-09-10

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

30 enrolled

BreastGastrointestinal

Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT00617539 2018-04-20

Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases

30 enrolled 10 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT00303992 2018-01-17

Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer

9 enrolled

Breast Neoplasms

NCT00004095 2017-04-18

Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors

BreastGastrointestinalGenitourinaryThoracic

38 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT00079118 2016-12-13

Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer

70 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT00275041 2016-12-13

Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer

21 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT00003351 2016-07-14

Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer

104 enrolled

Breast Neoplasms

NCT00693719 2015-11-20

Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer

31 enrolled 8 charts

Breast Neoplasms

NCT00031681 2013-09-30

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

41 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00004182 2012-06-06

Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer

Breast Neoplasms

NCT00083148 2011-03-09

Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer

12 enrolled

Breast Neoplasms

NCT00072852 2008-10-16

Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine

134 enrolled